Observational studyOrphanet journal of rare diseases2026
Longitudinal assessment of the retinal phenotype in patients with Fabry disease undergoing continuous enzyme replacement and/or chaperone therapy.
Observational study in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by deficiency of the enzyme α-galactosidase A. This study describes the long-term evolution of retinal findings in genetically confirmed FD patients, who have been receiving enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT).
methodsThis retrospective observational study included 42 eyes of 21 patients, who underwent comprehensive ophthalmic examination including best-corrected visual acuity (BCVA) testing, tonometry, slit-lamp biomicroscopy of the anterior eye segment, fundus examination and spectral-domain optical coherence tomography (OCT) imaging. Longitudinal analysis focused on the central retinal thickness (CRT), peripapillary retinal nerve fiber layer (RNFL) thickness, intraretinal hyperreflective foci (HRF), and retinal vessel tortuosity.
resultsOver a median follow-up period of 6.5 years, BCVA remained stable in all patients. Serum lyso-globotriaosylceramide (lyso-Gb3) levels demonstrated strong correlations with intraretinal HRF and retinal vessel tortuosity but no significant change during the observation period was observed. Longitudinal assessment showed no significant change of HRF, retinal vessel tortuosity or CRT over time, whereas a significant reduction of RNFL thickness was observed, although these values remained within the normal range.
conclusionLong-term treatment with ERT or PCT in FD is associated with a largely stable retinal phenotype. Retinal imaging parameters remain structurally preserved over time, with only mild RNFL thinning observed, suggesting limited progressive retinal neurodegeneration.
Indexed as
Identifiers
42850619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.